Company Description
Tenaya Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and delivers therapies for heart disease in the United States.
Its lead product candidate includes TN-201, a gene therapy for myosin binding protein C3-associated hypertrophic cardiomyopathy that is in Phase 1b/2 clinical trial; TN-401, a gene therapy for plakophilin 2-associated arrhythmogenic right ventricular cardiomyopathy, which is in Phase 1b/2 clinical trial; and TN-301, a small molecule histone deacetylase-6 for heart failure with preserved ejection fraction that is in phase 1 clinical trial.
The company develops its products through gene addition, gene editing, gene silencing, and cellular regeneration.
It has a research collaboration agreement with Alnylam Pharmaceuticals, Inc. to identify and validate novel gene targets for the potential treatment of cardiovascular disease.
Tenaya Therapeutics, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.
| Country | United States |
| Founded | 2016 |
| IPO Date | Jul 30, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 70 |
| CEO | Faraz Ali |
Contact Details
Address: 171 Oyster Point Boulevard, Suite 500 South San Francisco, California 94080 United States | |
| Phone | 650 825 6990 |
| Website | tenayatherapeutics.com |
Stock Details
| Ticker Symbol | TNYA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $15.00 |
| CIK Code | 1858848 |
| CUSIP Number | 87990A106 |
| ISIN Number | US87990A1060 |
| Employer ID | 81-3789973 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Dr. Deepak Srivastava M.D. | Scientific Founder, Chairman of Scientific Advisory Board and Director |
| Dr. Whittemore G. Tingley M.D., PH.D. | Chief Medical Officer |
| Dr. Eric N. Olson Ph.D. | Scientific Founder and Member of Scientific Advisory Board |
| Dr. Bruce R. Conklin M.D. | Scientific Founder |
| Dr. Saptarsi Haldar M.D. | Scientific Founder |
| Dr. Sheng Ding Ph.D. | Scientific Founder |
| Dr. Benoit G. Bruneau Ph.D. | Scientific Founder |
| Dr. Kee-Hong Kim Ph.D. | Chief Technology Officer |
| Michelle Corral | Vice President of Investor Relationship and Corporate Communications |
| Jennifer Drimmer J.D. | General Counsel and Corporate Secretary |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 2, 2026 | 8-K | Current Report |
| Jun 29, 2026 | 8-K | Current Report |
| May 29, 2026 | 8-K | Current Report |
| May 6, 2026 | 10-Q | Quarterly Report |
| May 6, 2026 | 8-K | Current Report |
| Apr 16, 2026 | ARS | Filing |
| Apr 16, 2026 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 16, 2026 | DEF 14A | Other definitive proxy statements |
| Mar 11, 2026 | 10-K | Annual Report |
| Mar 11, 2026 | 8-K | Current Report |